Positive Clinical Results on the use of Bacterin's OsteoSponge for Transforaminal Lumbar Interbody Fusion (TLIF) Published in International Journal of Spine Surgery

Positive Clinical Results on the use of Bacterin's

OsteoSponge for Transforaminal Lumbar Interbody Fusion (TLIF) Published in International Journal of Spine Surgery

BELGRADE, Mont., November 21, 2013 /PRNewswire/

-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary

bone graft materials and coatings for medical applications, announces that the first clinical results using the OsteoSponge

product for transforaminal lumbar interbody fusion (TLIF) has been published in The International Journal of Spine Surgery.

The article reports a retrospective analysis of 82 total patients who underwent TLIF procedures using an acid-etched, roughened

titanium cage (Titan Spine's Endoskeleton TT) filled with OsteoSponge as a bone graft substitute. The study included a group

of patients evaluated at 6 months and a separate group of patients that were evaluated at 1 year post-op. An independent radiologist

reviewed and graded the CT scans for evidence of fusion and determined the fusion rates to be 41 of 44 (93.2%) for the 6 month

group and 37 of 38 (97.4%) for the 12 month group.

The article, titled "Transforaminal

lumbar interbody fusion rates in patients using a novel titanium implant and demineralized cancellous allograft bone sponge,"

concluded that results using the Endoskeleton TT cage and OsteoSponge achieved similar fusion rates to historical controls of using

Iliac Crest Bone Graft (ICBG) or recombinant human BMP-2 (rhBMP-2) in conjunction with a polyetheretherketone (PEEK) cage implant.

"We have long understood that our

product can achieve excellent results for various spinal fusion procedures, however, having our first spine-focused publication

further validates the use of OsteoSponge as a bone graft substitute," said Dan Goldberger, Bacterin's CEO and President.

"We couldn't be more pleased with the outcomes reported in this study."

About Bacterin International

Bacterin International

Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. These

products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone

growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other

Bacterin's Medical Device

division develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures

that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that

are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature,

that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts,"

"expects," "anticipates," "intends," "plans," "believes," "estimates,"

"projects," "forecasts," "strategy," "will," "goal," "target," "prospects,"

"potential," "optimistic," "confident," "likely," "probable" or similar expressions

or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these

statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of

important factors, including, among others: the Company's ability to meet its existing and anticipated contractual obligations,

including financial covenant and other obligations contained in the Company's secured lending facility; the Company's

ability to manage cash flow and achieve profitability; the Company's ability to develop, market, sell and distribute desirable

applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve

expected results; the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to

obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain

management and employees with appropriate skills and expertise; the Company's ability to successfully conclude government

investigations; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including

actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and

Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly

any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence

of unanticipated events, except as required by law.